Dog Mast Cell Tumour Grade III Management

Grade III mast cell tumours are highly malignant skin cancers in dogs requiring aggressive multimodal treatment, and welfare considerations inform decisions about treatment intensity and endpoint.

Key Facts

Mast cell tumours are the most common malignant skin tumour in dogs
Grade III tumours show high mitotic activity and carry a poor prognosis with median survival of months
Tyrosine kinase inhibitors including toceranib and masitinib have improved treatment options
Wide surgical excision is the cornerstone of treatment when the tumour is resectable
Regional lymph node assessment and staging are important for prognosis and treatment planning
Systemic metastasis to liver, spleen, and bone marrow significantly worsens prognosis

Welfare Considerations

Grade III mast cell tumours cause significant welfare harm through local tissue invasion, pruritus from histamine release, gastrointestinal complications from systemic mast cell mediators, and the systemic effects of widespread metastatic disease. Treatment decisions must balance the potential for disease control against treatment burden and side effects. Chemotherapy and tyrosine kinase inhibitors can cause nausea, lethargy, and immune suppression. Welfare-centred oncology involves regular quality of life assessment and a willingness to transition to palliative care when treatment burden exceeds benefit.

What You Can Do

Seek specialist veterinary oncology referral promptly for a suspected or confirmed Grade III MCT
Discuss quality of life monitoring and treatment endpoints clearly with your oncologist
Use a validated quality of life assessment tool to track your dog welfare during treatment
Ensure gastrointestinal protection with antihistamines and proton pump inhibitors during MCT management
Support veterinary oncology research into improved targeted therapies for high-grade MCT